Novel Repositioning Therapy for Drug-Resistant Glioblastoma: In Vivo Validation Study of Clindamycin Treatment Targeting the mTOR Pathway and Combination Therapy with Temozolomide.

导出 OA

翻译打印收藏纠错

作者： Takeyoshi,Eda ^[1] ; Masayasu,Okada ^[2] ; Ryosuke,Ogura ^[2] ; Yoshihiro,Tsukamoto ^[2] ; Yu,Kanemaru ^[2] ; Jun,Watanabe ^[2] ; Jotaro,On ^[2] ; Hiroshi,Aoki ^[2] ; Makoto,Oishi ^[2] ; Nobuyuki,Takei ^[3] ; Yukihiko,Fujii ^[2] ; Manabu,Natsumeda ^[2]

作者单位： Division of Pharmacy, Medical and Dental Hospital, Niigata University, Niigata 951-8520, Japan. ^[1] Department of Neurosurgery, Brain Research Institute, Niigata University, Niigata 951-8585, Japan. ^[2] Department of Brain Tumor Biology, Brain Research Institute, Niigata University, Niigata 951-8585, Japan. ^[3]

关键词 drug repositioning glioblastoma signal transduction xenograft model

DOI 10.3390/cancers14030770

PMID 35159037

发布时间 2022-02-19

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交